XML 36 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Segments (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Forth Disaggregated Research and Development Expenses

In addition to the significant expense categories included within net loss presented on the unaudited condensed consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Direct research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Budoprutug

 

$

5,288

 

 

$

4,521

 

 

$

10,651

 

 

$

10,662

 

CLYM1161

 

 

1,511

 

 

 

145

 

 

 

2,704

 

 

 

9,265

 

Legacy programs2

 

 

7

 

 

 

31

 

 

 

29

 

 

 

73

 

Unallocated research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Personnel-related (including stock-based compensation)

 

 

2,346

 

 

 

1,452

 

 

 

4,699

 

 

 

3,209

 

Other research and development expenses

 

 

562

 

 

 

426

 

 

 

1,004

 

 

 

693

 

Total research and development expenses

 

$

9,714

 

 

$

6,575

 

 

$

19,087

 

 

$

23,902

 

 

1 Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the six months ended June 30, 2025.

2 Includes direct expenses related to the Company’s legacy product candidates ETX-123 and ETX-155.